News

GID BIO – Investor Forum at the World Stem Cell Summit

Health
0 min read

GID BIO CEO Dr. William (Bill) Cimino delivers a formal corporate overview, followed by a Q & A session moderated by a Noble Capital Markets equity research representative.

Return to the Investor Forum Event Page

GID BIO has developed a tissue processing technology that enables point-of-care cellular therapies using a patient’s own cells for treatment of significant degenerative diseases, including osteoarthritis, peripheral vascular disease, degenerative diseases of the lung, and Parkinson’s Disease. Our biologic approach to therapy generates clinical results not achievable using drugs or devices.

Our device technology isolates and separates the healing stromal and vascular cells, including stromal progenitor cells, from the patient’s own adipose tissue at point-of-care, to leverage the most powerful healing capability known – the body’s innate and natural ability to heal itself. Our FDA-approved Phase IIb study showed that 85% of subjects responded greater than placebo at 1 year, with a median 87 % improvement in pain, stiffness, and function.

We have successfully completed Phase I and Phase II efforts and have launched an FDA-approved Pivotal/Phase III clinical trial for our technology and lead indication – degenerative osteoarthritis of the knee, the largest market opportunity in musculoskeletal disease.

We have a significant clinical pipeline for treatment of degenerative diseases – with pilot human data and development plans for osteoarthritis of the hands/spine, diabetic ulcers, and Parkinson’s Disease.

Share

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.